An interventional study of Training intervention in Osteoarthritis (OA) of the Knee and ACL Reconstruction, sponsored by Charite University, Berlin, Germany. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Osteoarthritis with a site in Germany — 12 open to participants now, 27 under way, 3 of them phase 3. Osteoarthritis · Germany.
Among the 131 studies in Osteoarthritis with a site in Germany, this one is the 68th largest by planned enrollment of the 98 interventional ones that give a count, is one of 6 that started in 2024, is one of 36 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 123rd registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →12 of the 131 studies in Osteoarthritis with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Argentina and 10 more countries
Ages 18+
University Hospital, Basel, Switzerland · Sites in Germany, Austria, Croatia and 5 more countries
Ages 18–70
University Hospital, Basel, Switzerland · Sites in Germany, Croatia, Switzerland
Ages 18–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–85
Waldfriede Hospital · Sites in Germany
Ages 18–90
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 24 · Phase 3 23 · Phase 4 12
First in 2000; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 139 across the 98 interventional studies, 100 across the 31 observational. Of the 96 that completed or were terminated, 28 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 131 have an industry lead sponsor. The 10 most frequent:
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
Charite University, Berlin, Germany has 4 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
7 of the studies in Osteoarthritis with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07352540Phase 3University of Erlangen-Nürnberg Medical SchoolSingle vs Triple Hyaluronic Acid in Knee Osteoarthritis | 2026-12-15 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT02351414MicroPort Orthopedics Inc.Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts | 2027-06 |
| NCT02823834MicroPort Orthopedics Inc.PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components | 2027-06 |
| NCT02038140Zimmer BiometZimmer Trabecular Metal Total Ankle PMCF | 2027-09 |
Add all 7 to your calendar (.ics) → With an account.
Among the 131 studies in Osteoarthritis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Osteoarthritis (OA) is a condition that causes pain and stiffness in the joints, often due to injuries like torn ligaments. Even after surgery, these injuries can lead to long-term joint problems. Current treatments don\'t fully prevent OA from developing. This study is testing a new 12-week exercise program designed to improve how the knee moves, using a special sensor-based system. The goal is to reduce joint inflammation and prevent the development of OA in patients who have had knee surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In addition to the standard-of-care physiotherapy program, the treatment group will additionally receive a training intervention utilizing sensor-based technology that provides 3D avatar training, supported by an accompanying app, to deliver personalized exercise regimens. This intervention aims to correct the pathological knee movement and loading patterns that exacerbate joint inflammation and contribute to the development of knee OA.
Behavioral: Training intervention
Standard-of-care physiotherapy program
Personalized digital training intervention aims to correct pathological knee movement and loading patterns and reduce inflammation in pre-stage knee osteoarthritis.
Primary Endpoint
Restoration of normal knee angle and moment patterns during walking at 6-month follow-up (compared to normative data), as determined by a machine learning-derived gait index.
Time frame: at 6-month follow-up visit
Secondary Endpoint: Cartilage Thickness
Quantitative magnetic resonance imaging measurement of cartilage thickness, expressed in millimeters (mm), across predefined articular sub-regions of the knee.
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Cartilage Volume
Quantitative magnetic resonance imaging measurement of cartilage volume, expressed in cubic millimeters (mm³), across predefined articular sub-regions of the knee.
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Cartilage Composition
Quantitative magnetic resonance imaging measurement of cartilage composition using laminar T2 relaxation time, expressed in milliseconds (ms), reflecting cartilage water content and collagen organization across predefined articular sub-regions of the knee.
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Meniscus Position
Quantitative magnetic resonance imaging measurement of meniscus extrusion, expressed in millimeters (mm), defined as the distance the meniscus extends beyond the edge of the tibial plateau.
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Hoffa Synovitis
Quantitative magnetic resonance imaging measurement of Hoffa synovitis, expressed as a signal distribution pattern (dimensionless) within the infrapatellar (Hoffa's fat pad) region.
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Effusion Synovitis
Quantitative magnetic resonance imaging measurement of joint effusion and synovitis, expressed as synovial fluid volume in cubic millimeters (mm³).
Time frame: Baseline, 6, and 36 months follow-up visits
Secondary Endpoint: Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS)
Semi-quantitative assessment of structural pathology using the Magnetic Resonance Imaging Osteoarthritis Knee Score (MOAKS), where scores range from 0 (no cartilage damage) to 3 (severe cartilage damage), with higher scores indicating greater pathology, across fourteen articular sub-regions.
Time frame: Baseline, 6, and 36 months follow-up visits
Exploratory Endpoint: Biomarkers of Joint Tissue Remodeling
Circulating and synovial fluid markers of joint tissue remodeling (e.g., CTX-I, CTX-II, PRO-C2, C1M) will be measured using validated immunoassays with detection limits in the nanogram-per-milliliter (ng/mL) range.
Time frame: Baseline, 6, and 36 months follow-up visits
Exploratory Endpoint: Inflammatory Cytokines
Plasma or serum concentrations of inflammatory cytokines and soluble mediators (e.g., TNF-α, G-CSF, IFN-γ, IL-6) will be determined using validated multiplex immunoassays with detection limits in the picogramm-per-milliliter (pg/mL) range.
Time frame: Baseline, 6, and 36 months follow-up visits
Exploratory Endpoint: Cellular Biomarkers
Immune cell subpopulations in peripheral blood and synovial fluid are analyzed by standardized multiparameter flow cytometry for basic phenotyping of T cells, B cells and myeloid cell populations and reported either as absolute or relative cell count.
Time frame: Baseline, 6, and 36 months follow-up visits
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 37 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 37 months is above that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →